
News|Podcasts|May 5, 2025
Novel HER2-low Therapies and Pharmacist-Led ADC Sequencing
Author(s)Alexandra Gerlach, Editor
This installment of our series on ADCs and HER2 breast cancer offers key insights about novel agents in clinical trials and management of ADC therapies.
Advertisement
In this episode of the Pharmacy Times Peer Exchange feature series about antibody drug conjugates (ADCs) and human epidermal growth factor receptor 2 (HER2) breast cancer (BC), oncology pharmacists continue their discussion and move onto emerging therapies in HER2-negative and HER2-low metastatic BC. Hosted by Rose DiMarco, they also share key insights about the role of pharmacists in guiding ADC therapy sequencing.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
SGLT2 Inhibitors in T2D Lower 5-Year Risk of CKD and Acute Kidney Injury
3
Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
4
Balancing Survival and Quality of Life in Pancreatic Cancer: Expert Perspectives From an Immuneering Panel
5


























